• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Hospitalized COVID-19 patients show decrease in mortality with dexamethasone

byConstance Wu
March 9, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care.

2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although the majority of coronavirus disease 2019 (COVID-19) cases are asymptomatic or have minor symptoms, patients need hospital care which can progress to respiratory failure and require ventilatory support. Furthermore, no therapeutic agent has been shown to reduce mortality in this subset of patients. As such, this study assessed the use of dexamethasone in patients hospitalized with COVID-19. The study determined mortality at 28 days was significantly lower in the dexamethasone group compared to the usual care group. Additionally, no benefit was found amongst patients who did not require oxygen. Patients treated with dexamethasone were also noted to have a shorter duration in their hospital stay and a greater probability of being discharged within 28 days. The study was limited by the lack of long-term follow-up in patients treated with dexamethasone. Nonetheless, this study’s results are significant, and its findings have led to updated treatment guidelines for patients hospitalized with COVID-19 on ventilatory support.

Click to read the study in NEJM

Relevant Reading: Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review

In-Depth [randomized controlled trial]: This controlled, open-label trial enrolled 6,425 patients.  Eligible patients included those with confirmed SARS-CoV-2 infection, hospitalized for severe symptoms, and on ventilation or oxygen support. Patients were excluded if dexamethasone was not available at the hospital. Randomization occurred in a 2:1 ratio to receive either usual care alone or usual care plus dexamethasone (oral or IV 6 mg daily), respectively. The primary endpoint was all-cause mortality within 28 days after randomization. Overall, mortality at 28 days was significantly lower in the dexamethasone group (mortality, 482 of 2104 patients; 22.9%) compared to patients in the control group (mortality, 1110 of 4321; 25.7%) (rate ratio, 0.83; 95% confidence interval [Ci], 0.75 to 0.93; P<0.001). Subgroup analysis showed there was no benefit in treating patients who did not receive respiratory support with dexamethasone (17.8%) compared to usual care alone (14.0%) (rate ratio, 1.19; 95% CI, 0.92 to 1.55). Furthermore, patients treated with dexamethasone (median, 12 days) had a shorter duration in the hospital compared to the control group (median, 13 days). Finally, patients treated with dexamethasone had a greater probability of discharge after 28 days compared to usual care alone (rate ratio, 1.10; 95% CI, 1.03 to 1.17). Taken together, dexamethasone was shown to decrease all-cause mortality, shorten the duration of hospital stay, and improve the probability of discharge in hospitalized patients with COVID-19.

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusdexamethasoneSARS-CoV-2ventilation
Previous Post

Ad26-vectored vaccine induces strong Zika virus neutralizing activity

Next Post

Neurologic involvement in children and adolescents with COVID-19 or multisystem inflammatory syndrome

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Neurologic involvement in children and adolescents with COVID-19 or multisystem inflammatory syndrome

Sunitinib showed no change in overall survival for metastatic prostate cancer

Radiolabeled Lutetium-177 offers higher PSA response versus cabazitaxel in metastatic castration-resistant prostate cancer

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.